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Abstract 
Background: Celiac disease is challenging to recognize, predisposing to long diagnostic 
delay. Currently, associated factors and significance of the delay remain obscure. Objective: 
The objective of this article is to investigate associated sociodemographic risk factors and 
health consequences of diagnostic delay in celiac disease. Methods: Altogether 611 patients 
were surveyed at diagnosis and after one year on a gluten-free diet regarding 
sociodemographic variables, well-being and use of medicines and health care services. 
Quality of life was measured by a validated Psychological General Well-Being (PGWB) 
questionnaire. The results were compared between patients with and without delayed (≥ 3 
years) diagnosis. Results: A total of 332 (54%) individuals reported a delay of ≥ 3 years. 
Associated with the delay were being a student or homemaker, but not gender, marital or 
occupational status, site of diagnosis or place of residence. Patients with the delay also had 
decreased self-perceived health and poorer PGWB scores compared to those without delay; in 
anxiety and general health this was seen even on a gluten-free diet. Days of sickness and 
doctor visits as well as use of drugs for dyspepsia and antidepressants were increased in the 
delay group both before and after diagnosis. Conclusion: A delay in celiac disease diagnosis 
predisposes to reduced well-being and incremental use of medicines and health care services, 
both before diagnosis and one year after diagnosis. 
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Key summary 
 
Established knowledge on this subject: 
• Celiac disease is a very common but markedly unrecognized condition. 
• Median diagnostic delay of the disease is as long as from three to 13 years. 
• At present, factors underlying and consequences of the delay remain mostly obscure. 
 
New ﬁndings of this study: 
• A diagnostic delay of only three years is associated to decreased quality of life and 
excess doctor visits, days of sickness and use of pharmaceutical agents before 
diagnosis. 
• Many of the detriments associated with the delay may remain overrepresented even 
during the year after diagnosis. 
• Being a student or homemaker is associated with reduced risk of delay, whereas no 
other associations with socioeconomic factors were found. 
 
Introduction 
 
Celiac disease is a gluten-induced immunological disorder with an estimated prevalence of as 
high as 1%– 2% in Western countries (1). The diverse clinical picture of the disease is a 
challenge to physicians, and at present approximately 75%–90% of aﬀected individuals 
remain unrecognized (2,3). In clinical practice, a mean diagnostic delay of up to even 13 
years has been reported (4–8). Long-term untreated celiac disease predisposes to severe 
complications such as osteoporosis, infertility and lymphoma (9–11), and there is also 
evidence to suggest that in undiagnosed but symptomatic patients incremental use of health 
care services and pharmaceutical agents is likely (4,8,12,13). 
 
Another concern possibly associated with a delay in diagnosis is poor quality of life, as many 
untreated celiac patients suﬀer reduced psychological well-being, which improves on a 
gluten-free diet (14–16). Currently it remains unclear what factors are associated with the 
delay, and whether the delay aﬀects patients’ self-perceived health. In addition, it is not 
known whether the delay predisposes to long-term increased consumption of medicines and 
consultations with physicians, which could be prevented by early diagnosis and dietary 
treatment of celiac disease. 
 
In this prospective study, we investigated a number of patient-centered factors associated 
with diagnostic delay in celiac disease, and the eﬀect of one year on a glutenfree diet on 
these. In particular, we aimed to evaluate the role of variable sociodemographic factors in the 
delay, and whether the delay is associated with individual health burden and increased use of 
health care services and pharmaceutical agents. 
 
Methods 
 
Participants and study design 
 
The study was conducted in collaboration with the Finnish Celiac Society, which 
approximately 70% of new celiac disease patients in Finland join soon after diagnosis (14). 
During a nationwide enrollment, a structured and validated questionnaire was sent to all new 
members joining the society in years 2007 and 2008. The patients were diagnosed at all 
health care levels from primary to tertiary care. Respondents older than 16 years of age with 
biopsy-proven celiac disease diagnosed within one year were considered eligible and 
continued in the study. Exclusion criteria were uncertain celiac disease diagnosis and lack of 
information on the duration of symptoms leading to the diagnosis. A follow-up questionnaire 
was sent to all participants after one year on a gluten-free diet. No ethical committee review 
was obtained because this was a questionnaire-based survey. However, informed consent was 
obtained from all participants after a written explanation of the aims of the study, including 
considerations regarding ethics and data protection and the anonymous deposition of the 
questionnaire. 
 
Celiac disease diagnosis was considered delayed (‘‘delay group’’) if the disease-related 
symptoms had lasted at least three years before diagnosis, according to the previously shown 
median diagnostic delay in Finland (8). Speciﬁc symptoms leading to celiac disease diagnosis 
have been deﬁned elsewhere in detail (14). Participants were further categorized on the basis 
of place of residence into individuals living in the South/ West and those living in the 
North/East areas of the country, and also into those living either in urban or in rural areas. 
The South/West region of Finland has a markedly higher population density (41.7 
inhabitants/ km2) than the North/East (6.4 inhabitants/km2) (17). An urban area was deﬁned 
as a population center with more than 15,000 inhabitants according to the Finnish 
Environmental Administration (18). 
 
Questionnaires 
 
The baseline and follow-up questionnaires were designed in cooperation with celiac disease 
patients 
and the Finnish Celiac Society. They comprised questions on a variety of sociodemographic 
aspects and the patients’ perceptions of the impact of the diagnosis on their overall health and 
well-being. Particular attention was paid to the duration of symptoms before diagnosis, 
occupational and working position, place of residence, site of ﬁrst suspicion and diagnosis of 
celiac disease (primary, secondary or tertiary care), and self-rated health, concern for health, 
burden of symptoms and reaction to the celiac disease diagnosis both at the time of diagnosis 
and after one year on a gluten-free diet. Self-estimated health was rated on a four-point Likert 
scale as excellent, good, fair or poor; in analysis excellent and good were combined. Concern 
for personal health and burden of symptoms ranged from ‘‘not at all’’ to ‘‘extremely’’ on a 
three-point Likert scale. The participants also reported the number of all-cause visits to health 
care providers, consumption of pharmaceutical agents and days of absence from work during 
the year before diagnosis and in the ﬁrst year on a gluten-free diet. Moreover, patients were 
asked about adherence to the gluten-free diet after one year on the diet. 
 Health-related quality of life 
 
In addition to the above survey, self-estimated quality of life was measured by the structural 
Psychological General Well-Being Questionnaire (PGWB) both at diagnosis and after one 
year of a gluten-free diet. PGWB is a well-validated and widely used questionnaire in general 
and also in celiac disease research (15,16,19). It consists of 22 items, each using a six-grade 
Likert scale, with higher scores indicating better psychological well-being. The questionnaire 
is further subdivided into six subdimensions, each containing three to ﬁve separate items: 
anxiety, depression, well-being, self-control, general health and vitality. The total PGWB 
score is the sum of all 22 items and may thus range from 22 to 132 points. 
 
Statistics 
 
The feasibility of the study questions was pretested by a group of celiac disease patients as 
previously described in detail (20). Brieﬂy, for test-retest reliability, 11 treated patients 
repeated the questionnaire one week after the ﬁrst contact and the intraclass correlation 
coeﬃcient was measured. The kappa values ranged from 0.84 to 1.00, being thus considered 
excellent (> 0.70). Statistical analysis was carried out using the Statistical Package for the 
Social Sciences Statistics, version 20.0 (IBM, Armonk, NY, USA). Binary logistic regression 
analysis was used to identify category factors associated with diagnostic delay. The results 
are shown as odds ratios (ORs) with 95% conﬁdence interval (CI). A p value <0.05 was 
considered signiﬁcant. Quantitative data were analyzed by independent-samples t test for 
normally distributed variables and by Mann-Whitney U test for skewed variables. The use of 
pharmaceuticals was divided into any use or no use of certain medicines and analyzed by 
Chi-square test. In order to make the results more comprehensive, both range and medians 
with quartiles are shown in Table 4. All data were blindly coded before statistical analysis. 
 
Results 
 
Altogether 1062 (57%) of the 1864 new members joining the Celiac Society during the study 
period responded. Of these, 451 were excluded: 157 as not being diagnosed within one year, 
132 for being younger than 16 years of age, 89 for a lack of information regarding the 
duration of symptoms or otherwise substantially missing data and 73 owing to unclear celiac 
disease diagnosis. Of the 611 eligible individuals, 559 (91%) also completed the follow-up 
questionnaire. Seventy-six percent of the ﬁnal study cohort were women. 
 
The median duration of symptoms before celiac disease diagnosis was three (range 0–50) 
years and in 332 (54%) cases diagnosis was delayed by at least three years. Median age at 
diagnosis was 50 (16–75) years in patients with a delay and 48 (17–82) years in those without 
a delay (p=0.363). Of the various sociodemographic characteristics, being a student or 
homemaker was associated with reduced risk of diagnostic delay compared with being 
employed (Table 1). In contrast, gender, marital or occupational status, position at workplace, 
geographical residence and site of ﬁrst suspicion or eventual diagnosis of celiac disease had 
no association with the risk of delay (Table 1). 
 
All 559 individuals who returned the follow-up questionnaires were on a gluten-free diet, but 
64 (11%) reported occasional lapses. On the diet the symptoms disappeared completely in 
130 (23%), were alleviated in 337 (60%), remained unchanged in 71 (13%) and increased in 
three (0.5%) people. The likelihood of symptoms persisting on a gluten-free diet was 
increased in those with diagnostic delay (OR 1.61, 95% CI 1.08–2.42, p=0.022). 
 
Diagnostic delay was associated with the risk of poor or only fair self-estimated health and 
concern about health at celiac disease diagnosis (Table 2). After one year on a gluten-free 
diet, there was no longer a diﬀerence between the groups in self-perceived health, but 
concern about health remained higher in patients with the delay. Further, these individuals 
more often reported a moderate or extreme burden of symptoms at diagnosis and experienced 
feeling relief (compared to upset or confused) after the diagnosis in comparison to patients 
with no delay (Table 2). 
 
PGWB total and all subscores were signiﬁcantly lower at diagnosis in patients with delayed 
diagnosis compared to those without (Table 3). On dietary treatment, the scores improved in 
both groups, but anxiety and general health scores remained lower in the delay group (Table 
3). 
 
The numbers of outpatient visits in primary health care and days of sickness during the year 
prior to celiac disease diagnosis were higher in individuals with diagnostic delay compared to 
those without (Table 4). The frequency of visits decreased in both groups during the year 
following diagnosis, but the diﬀerence remained signiﬁcant. In contrast to outpatient visits, 
the number of days of sickness increased in both groups on a gluten-free diet (Table 4). 
 
The proportion of patients using analgesics, drugs for dyspepsia and antidepressants was 
increased in patients with diagnostic delay compared to those without during the year before 
diagnosis, and the diﬀerence in the two latter remedies remained signiﬁcant on a gluten-free 
diet (Table 5). There was a similar but nonsigniﬁcant trend with antibiotics in the year before 
diagnosis (Table 5). Comparable differences between the delay group and controls were seen 
when the use of pharmaceutical agents was analyzed according to amount of pills per month 
(data not shown). 
 
Discussion 
 
Our main ﬁnding was that as little as three years’ diagnostic delay in celiac disease is 
associated with reduced health and well-being and increased use of health care and 
medicines. In fact, many of these detriments remained overrepresented in the delay group 
even during the year after diagnosis. Since in many countries the median delay is as high as 
9–13 years (4–7), the morbidity observed here in patients with a substantially shorter period 
is alarming. Although part of these problems may eventually be alleviated on a gluten-free 
diet, it seems that a considerable number of celiac patients suﬀer from an excess health and 
economic burden avoidable by earlier diagnosis. 
 
One of the key ﬁndings here was the reduced self-perceived health and psychological well-
being in patients with a diagnostic delay. This is in accord with a previous Swedish study 
likewise showing poorer quality of life at diagnosis in those with a long delay (7). Here, some 
of these important clinical outcomes remained poorer even after one year on a gluten-free 
diet, indicating that recovery from the psychological burden associated with long-term 
unrecognized celiac disease takes some time. Moreover, although the matter remains 
somewhat controversial (15,21), there is previous evidence that a subgroup of patients may 
continue to suﬀer from persistent poor health and mental problems even after years on a 
gluten-free diet (7,16). It is therefore essential that physicians and other health care 
professionals devote particular attention and support to those with a markedly delayed celiac 
disease diagnosis. 
 
Somewhat surprisingly, we found no association between diﬀerent socioeconomic factors and 
diagnostic delay except for a lower risk in students and homemakers compared to those who 
were employed. The lack of other associations might be related to the long-term political goal 
to reduce inequalities in health and health care in Finland (22). Here, inexpensive and easily 
accessible public health care diagnoses and treats the great majority (in the present study 
89%) of celiac disease patients. Because of the diﬀerences in health care systems, some 
caution is needed before extrapolating our ﬁndings to other countries. For example, more 
variability exists in terms of health care accessibility in the United States, where low income 
has been shown to be a major barrier to celiac disease diagnosis (23). Signiﬁcant regional and 
socioeconomic variation in the prevalence of celiac disease has also been observed in the 
United Kingdom, possibly reﬂecting disparities in health-seeking behavior and/or access to 
correct diagnostic pathways (24). The somewhat counterintuitive lower risk of delay in 
students and homemakers noted here might be explained by the well-organized student health 
care and maternity clinics in Finland (25,26). Although there are no other similar studies, 
Vavricka and colleagues (27) have previously shown age younger than 30 years, the typical 
age for students and homemakers, to be associated with reduced risk of diagnostic delay. 
 
Neither place of residence nor level of health care at which the celiac disease diagnosis was 
made was associated with the risk of diagnostic delay. This is compatible with our previous 
ﬁndings in patients with a delay of 10 years diagnosed mostly in the area of one tertiary 
center (28), whereas the earlier mentioned British study reported signiﬁcant regional 
diﬀerences in the diagnostic delay (24). The low regional variation in Finland is very likely 
aﬀected by the frequently updated nationwide Current Care Guidelines for celiac disease 
(29). The guidelines aim to increase awareness and diagnostic eﬃcacy in celiac disease 
particularly in primary care. 
 
As a result of this decentralization the prevalence of diagnosed celiac disease in Finland is 
among the highest in the world (28,30). There are no studies from other countries evaluating 
the eﬀect of such a reorganization of celiac disease diagnostics, but the issue has been 
investigated for instance in inﬂammatory bowel disease and chronic lung diseases, with 
somewhat less promising results (31,32). We believe that primary care diagnostics can be 
very successful, but only if combined with practical diagnostic tools and continuous 
education of physicians. 
Patients in the delay group reported more primary health care visits and days of sickness both 
in the year prior to and following the diagnosis. One reason leading to excess visits and ill 
health could be the often vague and unspeciﬁc symptoms not being recognized as celiac 
disease (33). The higher use of health care even after the diagnosis might be related to our 
previous observation that diagnostic delay predisposes individuals to persistent symptoms on 
a gluten-free diet (16). The increased number of days of sickness probably occurs for the 
same reasons as the excess health care visits. Interestingly, a similar association between 
delayed diagnosis and increased work absence has been reported in endometriosis patients 
(34), further demonstrating diﬃculties encountered in cases of chronic diseases with a diverse 
clinical picture. The increased work absence in both study groups in the year following 
diagnosis can be explained for example by a severe infection season. 
 
There was also incremental use of analgesics, antidepressants and medicines for dyspepsia in 
the delay group in the year prior to the diagnosis. Previous studies have already shown 
excessive use of pharmaceuticals preceding celiac diagnosis (8,35), and this problem would 
appear to be further aggravated by delay. We could not trace the indications for these drugs, 
but they might have been prescribed for example in an attempt to ameliorate persistent 
gastrointestinal and depressive symptoms caused by unrecognized celiac disease (13,36). A 
parallel association between delay and excessive analgesic use before diagnosis has again 
been observed in endometriosis patients (37). In line with the lower quality of life and excess 
health care visits, the increased drug use continued even after the diagnosis. Besides slow 
resolution of symptoms, this might be due to patients’ reluctance to discontinue drugs they 
have used with some beneﬁts perhaps for several years. 
 
The main strengths of the study were its prospective design, the large nationwide patient 
cohort, validated questionnaires and broad range of relevant study outcomes. There was also 
an excellent response rate in the follow-up survey. On the other hand, questionnaire-based 
studies are prone to overrepresentation of healthy individuals who feel well, the risk of which 
is further aggravated by participants being members of celiac societies. It is also noteworthy 
that, although the treatment response was followed prospectively, outcomes and duration of 
symptoms before diagnosis were assessed retrospectively and are thus prone to recall bias. 
However, a recall period covering a maximum of one year in self-reported use of health care 
services and pharmaceutical agents has previously been shown to be reliable (38). The fact 
that the patients were enrolled almost 10 years ago might in theory have an eﬀect, but there 
have been no major changes in our health care system or celiac disease diagnostics, and we 
believe that the results are still representative. Finally, because of a lack of original patient 
records, we were unable to verify the self-reported medical information including celiac 
disease diagnosis, and to evaluate the possible impact of diﬀerent comorbidities on results. 
 
Conclusions 
 
We found even a relatively short diagnostic delay in celiac disease to be associated with 
increased health burden both at the individual and society level. Improved awareness of the 
diversity of the disease among physicians and at-risk group screening could be an eﬀective 
means to reduce the delay at the population level. 
 
 
 
Declaration of conflicting interests: None declared. 
 
Ethics approval: No ethical committee review was obtained because this was a questionnaire-
based survey. 
 
Funding: This work was supported by the Competitive Research Funding of Tampere 
University Hospital, the Sigrid Juselius Foundation, the Yrjo¨ Jahnsson Foundation and the 
Foundation for Pediatric Research. 
 
Informed consent: Informed consent was obtained from all participants after a written 
explanation of the aims of the study, including considerations regarding ethics and data 
protection and the anonymous deposition of the questionnaire. 
 
References 
1. Mustalahti K, Catassi C, Reunanen A, et al. Coeliac EU Cluster, Project Epidemiology. 
The prevalence of celiac disease in Europe: Results of a centralized, international mass 
screening project. Ann Med 2010; 42: 587–595. 
2. West J, Logan RF, Hill PG, et al. Seroprevalence, correlates, and characteristics of 
undetected coeliac disease in England. Gut 2003; 52: 960–965. 
3. Rubio-Tapia A, Ludvigsson JF, Brantner TL, et al. The prevalence of celiac disease in the 
United States. Am J Gastroenterol 2012; 107: 1538–1544. 
4. Cranney A, Zarkadas M, Graham ID, et al. The Canadian Celiac Health Survey. Dig Dis 
Sci 2007; 52: 1087–1095. 
5. Gray AM and Papanicolas IN. Impact of symptoms on quality of life before and after 
diagnosis of coeliac disease: Results from a UK population survey. BMC Health Serv Res 
2010; 10: 105. 
6. Green PHR, Stavropoulos SN, Panagi SG, et al. Characteristics of adult celiac disease in 
the USA: Results of a national survey. Am J Gastroenterol 2001; 96: 126–131. 
7. Norström F, Lindholm L, Sandstro¨ m O, et al. Delay to celiac disease diagnosis and its 
implications for healthrelated quality of life. BMC Gastroenterol 2011; 11: 118. 
8. Ukkola A, Kurppa K, Collin P, et al. Use of health care services and pharmaceutical agents 
in coeliac disease: A prospective nationwide study. BMC Gastroenterol 2012; 12: 136. 
9. Gasbarrini A, Torre ES, Trivellini C, et al. Recurrent spontaneous abortion and intrauterine 
fetal growth retardation as symptoms of coeliac disease. Lancet 2000; 356: 399–400. 
10. Corazza GR, Di Sario A, Cecchetti L, et al. Bone mass and metabolism in patients with 
celiac disease. Gastroenterology 1995; 109: 122–128. 
11. Holmes GK, Prior P, Lane MR, et al. Malignancy in coeliac disease—effect of a gluten 
free diet. Gut 1989; 30: 333–338. 
12. Dickey W and McConnell JB. How many hospital visits does it take before celiac sprue is 
diagnosed? J Clin Gastroenterol 1996; 23: 21–23. 
13. Card TR, Siffledeen J, West J, et al. An excess of prior irritable bowel syndrome 
diagnoses or treatments in celiac disease: Evidence of diagnostic delay. Scand J Gastroenterol 
2013; 48: 801–807. 14. Ukkola A, Mäki M, Kurppa K, et al. Diet improves perception of 
health and well-being in symptomatic, but not asymptomatic, patients with celiac disease. 
Clin Gastroenterol Hepatol 2011; 9: 118–123. 
15. Roos S, Karner A and Hallert C. Psychological wellbeing of adult coeliac patients treated 
for 10 years. Dig Liver Dis 2006; 38: 177–180. 
16. Paarlahti P, Kurppa K, Ukkola A, et al. Predictors of persistent symptoms and reduced 
quality of life in treated coeliac disease patients: A large cross-sectional study. BMC 
Gastroenterol 2013; 13: 75. 17. Statistics Finland. Population density by area, http:// 
tilastokeskus.fi/til/vaerak/tau.html (2014, accessed 14 September 2017). 
18. Finland’s Environmental Administration. Urban-rural classification, 
http://www.ymparisto.fi/kaupunkimaaseutuluokitus (2014, accessed 14 September 2017). 
19. Dimenas E, Carlsson G, Glise H, et al. Relevance of norm values as part of the 
documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J 
Gastroenterol Suppl 1996; 221: 8–13. 
20. Ukkola A, Ma¨ ki M, Kurppa K, et al. Changes in body mass index on a gluten-free diet 
in coeliac disease: A nationwide study. Eur J Intern Med 2012; 23: 384–388. 
21. Zingone F, Swift GL, Card TR, et al. Psychological morbidity of celiac disease: A review 
of the literature. United European Gastroenterol J 2015; 3: 136–145. 
22. Palosuo H and Sihto M. Reducing health inequalities in Finland: Progressing or 
regressing? Nordic Welfare Research 2016; 1: 55–64. 
23. Hafner-Eaton C. Physician utilization disparities between the uninsured and insured. 
Comparisons of the chronically ill, acutely ill, and well nonelderly populations. JAMA 1993; 
269: 787–792. 
24. West J, Fleming KM, Tata LJ, et al. Incidence and prevalence of celiac disease and 
dermatitis herpetiformis in the UK over two decades: Population-based study. Am J 
Gastroenterol 2014; 109: 757–768. 
25. Ministry of Social Affairs and Health Finland. Maternity and Child Health Clinics, 
http://stm.fi/en/maternity-andchild-health-clinics (accessed 14 September 2017). 
26. Kunttu K. Student health survey 2012: A national survey among Finnish university 
students 2012, http://www. yths.fi/filebank/2263-KOTT2012_in_English.pdf (2012, accessed 
14 September 2017). 27. Vavricka SR, Vadasz N, Stotz M, et al. Celiac disease diagnosis still 
significantly delayed—Doctor’s but not patients’ delay responsive for the increased total 
delay in women. Dig Liver Dis 2016; 48: 1148–1154. 
28. Fuchs V, Kurppa K, Huhtala H, et al. Factors associated with long diagnostic delay in 
celiac disease. Scand J Gastroenterol 2014; 49: 1304–1310. 
29. Finnish Medical Society Duodecim and the Finnish Society of Gastroenterology. Current 
care guideline: Coeliac disease, 
http://www.kaypahoito.fi/web/kh/suositukset/suositus?id¼hoi08001 (2017, accessed 14 
September 2017). 
30. Virta LJ, Kaukinen K and Collin P. Incidence and prevalence of diagnosed coeliac 
disease in Finland: Results of effective case finding in adults. Scand J Gastroenterol 2009; 
44: 933–938. 
31. Izquierdo JL, Martin A, de Lucas P, et al. Misdiagnosis of patients receiving inhaled 
therapies in primary care. Int J Chron Obstruct Pulmon Dis 2010; 5: 241–249. 
32. Vavricka SR, Spigaglia SM, Rogler G, et al. Systematic evaluation of risk factors for 
diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 496–505. 
33. Stasi E, Marafini I, Caruso R, et al. Frequency and cause of persistent symptoms in celiac 
disease patients on a long-term gluten-free diet. J Clin Gastroenterol 2016; 50: 239–243. 
34. Nnoaham KE, Hummelshoj L, Webster P, et al. Impact of endometriosis on quality of life 
and work productivity: A multicenter study across ten countries. Fertil Steril 2011; 96: 366–
373.e8. 
35. Mattila E, Kurppa K, Ukkola A, et al. Burden of illness and use of health care services 
before and after celiac disease diagnosis in children. J Pediatr Gastroenterol Nutr 2013; 57: 
53–56. 36. Smith DF and Gerdes LU. Meta-analysis on anxiety and depression in adult celiac 
disease. Acta Psychiatr Scand 2012; 125: 189–193. 
37. Staal AH, van der Zanden M and Nap AW. Diagnostic delay of endometriosis in the 
Netherlands. Gynecol Obstet Invest 2016; 81: 321–324. 
38. Longobardi T, Walker JR, Graff LA, et al. Health service utilization in IBD: Comparison 
of self-report and administrative data. BMC Health Serv Res 2011; 11: 137. 
  
   
Table 1. Association between diagnostic delaya and socio-demographic characteristics at 
diagnosis in 611 adults with celiac disease. 
 n Delay, % Odds ratio 95 % CI P value 
Gender      
Male 144 56 1   
Female 467 49 0.82 0.93 – 1.97 0.232 
Marital status      
Married/with partner 460 55 1   
Single 151 53 0.93 0.64 – 1.34 0.700 
Occupational status      
Employed 388 56 1   
Student or homemaker 56 36 0.43 0.24 – 0.78 0.005 
Unemployed 15 73 2.14 0.67 – 6.85 0.198 
Retired 138 53 0.88 0.59 – 1.29 0.876 
Position at workplace      
High 156 60 1   
Middle 145 55 0.83 0.53 – 1.32 0.436 
Low 279 52 0.74 0.50 – 1.11 0.143 
Geographical residence      
North and Eastb 159 52 1   
South and Westc 452 55 1.16 0.81 – 1.67 0.416 
Urban or rural residence      
Urban 351 56 1   
Rural 260 52 0.82 0.60 – 1.13 0.232 
First suspicion of disease      
Secondary/tertiary care 75 51 1   
Primary care 289 51 0.99 0.60 – 1.65 0.982 
Oneself, friend, family 214 58 1.37 0.81 – 2.32 0.245 
Site of diagnosis      
Secondary/tertiary care 283 52 1   
Primary care 325 56 1.16 0.84 – 1.60 0.361 
aCeliac disease related symptoms for 3 years or more before diagnosis. 
bPopulation density 6.4/km2. cPopulation density 41.7/km2. 
CI: confidence interval 
   
Table 2. Associations between diagnostic delaya and self-rated perceptions of health at diagnosis 
and one year after diagnosis in 611 adults with celiac disease. 
At diagnosis n Delay % Odds ratio 95 % CI P value 
Self-perceived health       
Good 242  47 1   
Fair 278  59 1.64 1.16 – 2.33 0.005 
Poor 87 60 1.70 1.03 – 2.79 0.037 
Concern about health      
Not at all 55 29 1   
Moderate 436 55 2.99 1.62 – 5.50 <0.001 
Extreme 117 63 4.20 2.10 – 8.39 <0.001 
Burden of symptoms      
Not at all 44 32 1   
Moderate 287 52 2.31 1.18 – 4.55 0.015 
Extreme 259 62 3.58 1.81 – 7.08 <0.001 
Reaction to the diagnosis      
Upset or confused 300 49 1   
Relieved 291 60 1.55 1.12 – 2.15 0.008 
      
One year after diagnosis 
Self-perceived health       
Good 411 53 1   
Fair 130  58 1.22 0.82 – 1.82 0.329 
Poor 17 53 1.01 0.38 – 2.66 0.990 
Concern about health      
Not at all 164 45 1   
Moderate 371 58 1.70 1.17 – 2.26 0.005 
Extreme 24 50 1.22 0.52 – 2.87 0.654 
aCeliac disease related symptoms for 3 years or more before diagnosis. 
CI: confidence interval 
   
Table 3. Psychological General Well-Being scores of 592 celiac disease patientsa at 
diagnosis and one year after diagnosis, categorized by length of diagnostic delay. 
 
 Delay ≥ 3 years   Delay < 3 years   
At diagnosis Mean (95% CI) Mean (95% CI) P valueb 
Total 87.1 (84.9 – 89.4) 93.6 (91.2 – 96.0) <0.001 
Anxiety 19.9 (19.3 – 20.5) 21.6. (20.9 – 22.2) 0.003 
Depressed mood 14.2 (13.9 – 14.5) 14.9 (14.5 – 15.2) 0.001 
Positive well-being 14.4 (14.0 – 14.9) 15.4 (14.9 – 15.9) <0.001 
Self-control 13.2 (12.8 – 13.5) 14.1 (13.7 – 14.4) <0.001 
General health 10.8 (10.5 – 11.1) 11.9 (11.6 – 12.3) <0.001 
Vitality 10.9 (10.5 – 11.2) 11.9 (11.5 – 12.3) <0.001 
    
One year after diagnosis   
Total 101.6 (99.6 – 103.5) 103.5 (101.5 – 105.6) 0.132 
Anxiety 23.3. (22.8 – 23.8) 24.0 (23.5. – 24.5) 0.048 
Depressed mood 16.0 (15.7 – 16.3) 16.2. (16.0 – 16.5) 0.220 
Positive well-being 16.7 (16.3 – 17.1) 17.1 (16.6 – 17.4) 0.339 
Self-control 14.9 (14.7 – 15.2) 15.0 (14.7 – 15.3) 0.628 
General health 13.0 (12.7 – 13.4) 13.6 (13.3 – 14.0) 0.009 
Vitality 12.8 (12.5 – 13.2) 13.2 (12.8 – 13.5) 0.070 
a592 patients at diagnosis and 580 after one year. bIndependent-sample T-test. 
CI: confidence interval 
   
Table 4. Use of health care services in the year prior to and following the diagnosis in 611 
celiac disease patients, categorized by length of diagnostic delay. 
  Delay ≥ 3 years   Delay < 3 years  
 Median  
(Q1,Q3) 
Range 
Median  
(Q1, Q3) 
Range P valuea 
Before diagnosis      
Doctor visitsb 3 (1, 5) 0-31 2 (1, 4) 0-30 0.002 
Days of sickness 0 (0, 5) 0-200 0 (0, 3) 0-180 0.020 
      
After diagnosis 
Doctor visitsb 2 (1, 4) 0-20 1 (0, 3) 0-15 <0.001 
Days of sickness 0 (0, 6) 0-356 0 (0, 4) 0-365 0.021 
aMann-Whitney U-test. bIn primary care. 
Q1, Q3:  lower and upper quartiles; CI: confidence interval. 
 Table 5. Proportion of patients using pharmaceutical agents in the year prior to and following the 
diagnosis in 611 celiac disease patients, categorized by length of diagnostic delay. 
 Delay ≥ 3 years  Delay < 3 years  
 %  % P valuea 
Before diagnosis n=330  n=279  
Analgesics 69.4  60.9 0.029 
Dyspepsia drugs 34.1  20.1 <0.001 
Antidepressants 11.0  5.4 0.014 
Sleeping pills 13.9  10.8 0.236 
Antibiotics 34.9  27.6 0.055 
Otherb 51.8  48.2 0.308 
     
After diagnosis n=301  n=258  
Analgesics 68.1  67.4 0.867 
Dyspepsia drugs 23.6  14.0 0.004 
Antidepressants 9.7  5.0 0.039 
Sleeping pills 14.0  11.2 0.337 
Antibiotics 28.9  26.5 0.520 
Otherb 55.5  56.6 0.793 
aChi-square test. bVitamins, micronutrients, herbal products. 
